Short-chain fatty acids: mediators between microbiota and host by Sánchez Buxens, Sara












































SHORT-CHAIN FATTY ACIDS: 
MEDIATORS BETWEEN 
MICROBIOTA AND HOST 
 
Grau en Nutrició Humana i Dietètica 
Departament de Nutrició, Ciències de l’Alimentació i Gastronomia  
Facultat de Farmàcia i Ciències de l’Alimentació  
Universitat de Barcelona 
 




End-of-Degree Project  
 
This work is licenced under a Creative Commons license. 
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AMPs  antimicrobial peptides  
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activated protein kinase  
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CLDN  claudin  
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H2O2  hydrogen peroxide  
Ig  immunoglobulin  
IL  interleukin   
MCD  microbial activity of 
carbohydrate degradation  
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transporter 1  
MUC2  mucin 2  
NDCs  non-digestible carbohydrates 
NIACR1  niacin receptor 1  
NPY  neuropeptide Y 
NRF2  nuclear factor erythroid 2-
related factor 2  
PEPCK  phosphoenolpyruvate 
carboxy-kinase  
PYY  peptide tyrosine-tyrosine 
ROS  reactive oxygen species  
RNS  reactive nitrogen species  
SCFA  short-chain fatty acids 
SOD2  superoxide dismutase-2  
SMCT-1  sodium-coupled 
monocarboxylate transporter 1  
Th2  T helper type 2  
TNF-α  Tumor necrosis factor alpha 
Treg  regulatory T cells 
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Abstract: A compelling set of links has emerged between the host's diet and the 
gut microbiota. In this regard, origin, type and quality of food shape the gut 
microbes and affect their composition. Could these links reflect the relationships 
that are established with the host's health or illness? A growing body of scientific 
work shows that metabolites produced from fermentation of dietary fiber by the 
microbiota influence host physiology. This review has been collected data from 
a key metabolites generated by the microbiota, the short chain fatty acids 
(SCFAs), showing that they are capable of modifying the physiology of the host 
at different levels: appetite regulation, glucose homeostasis, lipid metabolism, 
gut integrity and anti-oxidative, anti-inflammatory and immuno-modulatory 
effects. Therefore, the SCFAs could be a potential tool to be more studied and 
implanted in a future personalized nutrition.  
 
Keywords: gut microbiome; gut microbiota; dietary fiber; short-chain fatty acids; 
SCFA 
 
Resum: Ha sorgit un atractiu conjunt de vincles entre la dieta de l’hoste i la 
microbiota intestinal. En aquest sentit, l’origen, el tipus i la qualitat dels aliments 
determinen la composició i la funció dels microbis intestinals i afecten la seva 
composició. Podrien reflectir aquests enllaços les relacions que s’estableixen 
entre la salut o la malaltia de l’hoste? Un nombre creixent de treballs científics 
demostren que els metabòlits produïts a partir de la fermentació de la fibra 
dietètica per part de la microbiota influeixen en la fisiologia de l’hoste. En aquesta 
revisió s’han recollit dades d’uns metabòlits clau generats per la microbiota, els 
àcids grassos de cadena curta (AGCC), en què es demostra que aquests són 
capaços de modificar la fisiologia de l’individu a diferents nivells: regulació de 
la gana, homeòstasi de la glucosa, metabolisme lipídic, integritat intestinal i 
efectes antioxidatius, antiinflamatoris i immuno-moduladors. Per tant, els AGCC 
podrien ser una eina potencial per estudiar i implantar en una nutrició 
personalitzada futura. 
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1.1 The Human Gut Microbiota 
  The human gut microbiota is the result of a collection of microbes 
that live in the body. However, the largest and most diverse group of 
microorganisms inhabit the intestine, as it approaches the large intestine 
or colon [1]. Approximately 100 trillion microorganisms (bacteria, 
viruses, fungi and protozoa) exist in the human gastrointestinal tract 
and, for this reason, the microbiome is now considered as one more 
organ of the body [2]. The relationship established between the intestinal 
microbiota and the host is intimate and provides benefits for both, since 
the host provides a stable environment for microbes while they provide 
the host with a wide range of functions [1]. However, an aberrant 
composition of the gut microbiota, called dysbiosis, is associated with 
several diseases [1,3]. 
The important role that the intestinal microbiota seems to play in 
metabolism and, consequently, in human health, has contributed to 
research on the identification of specific microorganisms involved in 
different processes and the metabolic pathways in which they participate 
[3]. For this reason, in recent years, the gut microbiome has been the focus 
of different research developments that seem promising [4]. 
 
1.2 Factors Shaping the Gut Microbiota 
  Nowadays, it is known that the intestinal microbiota is affected not 
only by a single factor, but that there are different specific components 
to each individual, those that are internal (genetic, mode of birth and age) 
[5], and those that are external (breastfeeding, use of antibiotics, stress, 
sleep, physical activity and diet), which modulate the composition of the 
gut microbiota. 
 
1.2.1 Endogenous Factors: Genetic, Mode of Birth and Age 
           The genetic predisposition to develop a disease plays an important 
role. However, exposure to a certain environmental factor can exert 
pressure by increasing or decreasing the risk of suffering from it and with 
what severity. 
In addition, depending on whether the individual is born by 
cesarean section or vaginal delivery, the composition of the microbiota 
will vary. In the second case, when the newborn passes through the birth 
canal it is impregnated with bacteria from the mother's vaginal 
microbiota [6]. Thusly, the baby's intestinal microbiota is more diverse 
and healthier compared to babies born by cesarean section and, 
consequently, this greater diversity in the microbiota is associated with 
a lower risk of developing certain diseases or conditions [5,7]. 
In the same way, another important factor that affects the 
composition of the microbiota is the age. In advanced ages, obvious 
morphological changes of the intestine appear, such as shortening and 
atrophy of the intestinal villi and a reduction in the surface of the 
intestinal mucosa. Hence, the habitable place for the microbiota 
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decreases and its diversity is reduced, also causing a reduction in the 
absorptive capacity of nutrients. 
 
1.2.2 Exogenous Factors: Breastfeeding, Use of antibiotics, Stress, Sleep, 
Physical Exercise and Diet 
Human breast milk provides the baby with optimal and complete 
nutrition, since its composition changes depending on the needs that the 
baby has to satisfy as it grows [8]. In addition, the variety of nutrients 
and bioactive molecules which it contains are of special importance for 
the correct growth and neurological development of the newborn and, 
therefore, breastfeeding plays a key role in modulating the intestinal 
microbial composition [5,9]. 
Several studies have been carried out to investigate the possible 
adverse effects of the use of antibiotics on the health of the mother and 
baby during pregnancy or near the time of birth [5]. These findings have 
shown that the administration of antibiotics has the potential to 
selectively alter the composition of the microbiota based on the type of 
antibiotic, the dose and the time it is taken. Consequently, this alteration 
presents some potential to lead to atopy, asthma, allergy and obesity in 
childhood [5,10,11]. 
The effect of stress on the gut-brain axis has been associated with 
changes in the gut microbiota, alterations in brain-derived neurotropic 
factor, behavioral changes, and can even lead to anxiety and depression 
[12]. This evidence highlights that the composition of the microbiota 
could represent a new strategy for the prevention of mental illnesses [5]. 
Another factor that modulates the gut microbiota is sleep. Both 
sleep fragmentation and short sleep duration are associated with the 
overgrowth of specific intestinal bacteria and lead to intestinal dysbiosis 
[13]. More specifically, intestinal microbial metabolites influence the 
expression of central and hepatic clock genes, as well as the duration of 
sleep in the host, and consequently regulate body composition through 
circadian transcription factors [14,15]. 
Exercise is one more factor which shape the gut microbiota. 
Despite that, the relationship between exercise and the microbiota is 
complex, because it is dependent on numerous variables like the 
intensity of exercise.  In more detail, it has been observed that in high 
intensity cases of exercise there is an increase in the permeability of 
dysbiotic bacteria and toxins in the intestinal mucosa leading to an 
inflammatory response. On the other hand, in cases of regular exercise 
this type of inflammatory response has not been observed [16]. 
A balanced diet meets all the nutritional requirements of 
carbohydrates, proteins, lipids, vitamins, minerals and water for proper 
body function, growth, and health. In further detail, carbohydrates are 
an important part of foods that provide energy and fiber [17]. In this 
second case, a high-fiber diet, including non-digestible carbohydrates, 
undergo bacterial fermentation in the gastrointestinal tract, obtaining 
different metabolites, which play a vital role in signaling pathways to 
maintenance a healthy gut microbiota. Nevertheless, with the 
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industrialization of the diet, low-fiber intake, high sugar and protein 
consumption, known as Western lifestyle, the diversity of the gut 




































Figure 1. Effect of low- and high-fiber diet on gut microbiota composition, 
diversity and function in relation to host physiology. Adapted from [18]. 
 
1.3 Functions of the Gut Microbiota 
The symbiosis that the human organism establishes with intestinal 
bacteria consists in the fact that the individual provides the residence and 
the food to survive to the bacteria and, on the other hand, these help to 
develop a series of essential functions for the organism [3]. 
The gut microbiota is a key factor in shaping the biochemical profile 
of the diet and, consequently, its impact on host disease and health [3]. 
The important role that the gut microbiota appears to play in human 
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metabolism and health has stimulated research to investigate the 
functions of the microbiota, which regulates the activation or inhibition 
of a many metabolic pathways [3]. 
 
1.3.1 Intestinal Barrier 
The microbiota can prevent the colonization by pathogenic 
microorganisms (bacteria, viruses, parasites, etc.). In the gastrointestinal 
tract there are epithelial cells which provide a physical barrier 
constituted of a single layer of different intestinal epithelial cells [21]. 
This barrier function is achieved thanks to the ability of bacteria to secrete 
antimicrobial substances that prevent the growth of potentially 
pathogenic microorganisms and it is a major line of defense. Therefore, 
intestinal barrier strongly participates in innate immunity and a 
dysbiosis on it could be related to increased susceptibility to certain 
diseases [21,22]. 
 
1.3.2 Immune System 
Another function that the microbiota performs is to stimulate the 
immune system [23]. The immune system of the intestinal mucosa is 
made up of three different mucosal lymphoid structures: Peyer's patches, 
the lamina propria, and the epithelium [23,24]. This system constitutes 
the largest immune component of the human being and, together with 
the intestinal microbiome, establish a close relationship. In this sense, the 
immune system of the intestinal mucosa is a key factor in homeostasis 
and host defense. However, once the balance is broken, it appears a 
dysfunction in host or an abnormal immune response which can lead to 
the development of intestinal diseases, such as inflammatory bowel 
disease, rheumatoid arthritis or systemic lupus erythematosus, among 
others [23]. 
 
1.3.3 Vitamin Synthesis  
The intestinal microbiota can synthesize different water-soluble 
vitamins, such as those of B group (thiamine, riboflavin, niacin, biotin, 
pantothenic acid and folate), critically involved in regular energy 
metabolism and enzymatic functions important for gene expression [25]. 
In addition, the intestinal microbiota can synthesize vitamin K (vitamin 
K2 or menaquinone), a fat-soluble vitamin necessary for coagulation, 
which the human body is not capable of synthesizing [26]. 
The effects of vitamins synthesized by the microbiota on the status 
of systemic vitamins are unclear for the time being. However, studying 
the interactions between the microbiota and vitamins can help to 
understand the effects of vitamins on the barrier function and immune 
system of the intestinal tract [24]. 
 
1.3.4 Carbohydrate Fermentation  
The gut microbiota helps to digest food and absorb nutrients. The 
microorganisms are in charge of digesting the foods which the digestive 
system cannot digest and, in return, they report beneficial substances for 
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the organism [23]. Dietary fibers, as well as proteins and peptides, which 
are not digested by host enzymes in the upper intestine, are substrates 
for the microbiota, especially in the cecum and the colon [1,18]. Thus, 
most of the soluble fibers are fermented by the microbial activity in the 
intestine and, once they are metabolized, short-chain fatty acids (SCFAs) 
and gases are generated [2,3]. More specifically, the main SCFAs 
produced are acetate, propionate and butyrate, which perform very 
different but develop highly relevant functions in the human body [2,3]. 
This process takes place in specific intestinal conditions, where anaerobic 
bacteria activate certain enzymes and metabolic pathways which allow 
complex carbohydrates to be metabolized [18]. However, it has been 
found that the concentration of SCFAs varies throughout the intestine, 
with the highest levels being in the cecum and proximal colon, while the 
lowest levels are found in the distal colon [1].  
 
1.4 Gut-Brain Axis 
The gut-brain axis corresponds to the bidirectional signaling 
mechanisms that exist between the gastrointestinal tract and the central 
nervous system [27]. Such communication can occur through multiple 
systems including the autonomic nervous system, the enteric nervous 
system, the immune system, and the neuroendocrine systems [27,28,29].  
Specifically, the enteric nervous system, which corresponds to the 
part of the autonomic nervous system in charge of controlling the 
digestive system, is recently known as the "second brain", because of its 
capability in acting as an independent entity of the central nervous 
system [30]. However, it is in constant communication with the 
autonomic nervous system (sympathetic and parasympathetic systems) 
[31]. In this regard, the enterochromaffin cells of the intestinal mucosa 
and the neurons of the enteric nervous system synthesize 50% of 
dopamine and 90% of serotonin, both of which modulate behavior 
[30,31]. Hence, a large number of studies report that SCFAs can 
participate directly or indirectly in communication through the gut-brain 
axis due to their neuroactive properties and the effects they exert on the 
signaling pathways that act on the endocrine and immune systems [27]. 
Thereby, the intestinal microbiota is an object of study to understand the 
close relationship that exists between intestinal health and mood, anxiety 
or depression, among others  [27,30,32]. 
 
2. Objectives 
The main objective of this work is to do an in-depth review to examine 
and summarize the available data on the influences of SCFAs 
synthesized by the gut microbiota on human health. 
In order to do so, more concrete aims will be achieved: 
a) To investigate what are SCFAs and to know their different pathways 
of metabolism. 
b) To do a deep examination of how SCFAs become the link to connect 
dietary fibers and gut microbiota to intestinal health. 
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c) To discuss the potential use of dietary fiber to modulate the microbiota, 
as well as the concept of personalized nutrition, like a new perspective 
for the future. 
 
3. Materials and Methods 
An extensive bibliographic search was carried out for the most 
reliable and up-to-date articles, reviews and books on the topic. To be 
able to accomplish that, PubMed®, developed by the National Center for 
Biotechnology Information (NCBI), was the aim resource in which this 
work is based, jointly Scopus®, the largest abstract and citation database 
of peer-reviewed literature. However, for  this search it has been used 
other bibliographic databases ("Cerca-bib" of the University of Barcelona 
and Google Scholar) and books on the subject written by recognized 
scientists. 
In all databases, the search strategy included these terms: “gut 
microbiota” [AND] “short-chain fatty acids”, “gut microbiota” [AND] 
“SCFA”, “gut microbiota” [AND] “diet”, “gut microbiota” [AND] 
“dietary fiber”. 
Thus, on September 4th 2020, the search for the articles began. Using 
each search strategy, approximately 2,600-10,500 articles were found. Of 
these, the search was narrowed by applying the filter of "publication 
date" to 5 years and the filter of "article type" to review. As a result, the 
number of articles found ranged from 90-700 and applying the filter of 
"publication date" of 5 years and the one of "article type" of meta-
analysis, up to 30 articles were obtained in total.  
Once a general overview of the different topics  was made, a more 
specific search was attained, joining the different sections and 
subsections of each topic. Thusly, having selected the information to be 
treated, the next step was to read it and to highlight the most relevant 
aspects to be discussed in this work, in order to present it in a 
summarized mode. 
Finally, Mendeley® was used to reference all the bibliography which 
appears in this this bibliographic research. 
 
4. Results 
4.1 SCFAs: Biosynthesis, Absorption and Distribution 
To break down carbohydrates into simpler sugars, humans have 
salivary α-amylase, an enzyme found in the oral cavity, and some other 
enzymes for the complete digestion of digestible carbohydrates acting in 
the intestinal lumen: pancreatic α-amylase, maltase, sucrase, galactose 
and lactase [17,33]. However, in the case of non-digestible carbohydrates 
(NDCs), they are metabolized by the microbial activity of carbohydrate 
degradation (MCD), obtaining the SCFAs as a result products [1]. Thus, 
dietary fiber which contains 10 or more monomeric units cannot be 
hydrolyzed by digestive enzymes and it is a substrate susceptible to 
bacterial fermentation in the colon, mostly producing (≥95%) acetate 
(C2), propionate (C3) and butyrate (C4), with a molar ratio of 60:20:20 in 
human feces, respectively [34,35] (Figure 2). In more detail, different 
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anaerobic microorganisms produce different proportion of SCFAs; 
however, Bacteroidetes (Gram negative) mainly produce acetate and 
propionate, while Firmicutes (Gram positive) generate butyrate as the 
metabolic end products [35]. 
Firstly, acetate is absorbed and transported by the portal vein [1]. It 
is the most abundant SCFA in the peripheral circulation and it has the 
ability to cross the blood-brain barrier [17]. In addition, in rat liver it is 
involved in cholesterol metabolism and lipogenesis and may play a role 



































Figure 2. a) Graphical abstract of dietary fiber and indigestible carbohydrates, 
which are made up of natural polymers [17]; b) Fermentation process of dietary 
fiber in the colon by the intestinal microbiota, indicating the metabolites 
produced (short chain fatty acids, SCFAs) and their main physiological functions. 
Modified from [17].  
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Secondly, propionate is absorbed and transported by the portal 
vein, as acetate too [1]. Furthermore, it is metabolized in the liver and, 
therefore, its concentration in peripheral organs is very low. Besides, it is 
able to regulate the state of satiety and the gluconeogenesis, through 
interaction with gut fatty acid receptors [2,37]. 
Thirdly, butyrate turns out to be the preferred energy source for 
colonocytes and is consequently consumed locally, maintaining oxygen  
balance in the  gut and preventing gut microbiota dysbiosis [2]. Different 
studies show the important role that butyrate plays in the proliferation, 
differentiation and integrity of rat colon cells [17,38]. Furthermore, it can 
induce apoptosis  of  colon  cancer  cells,  and  can  activate  intestinal  
gluconeogenesis,  having  beneficial effects on glucose and energy 
homeostasis [2].  
Hence, SCFAs have been the subject of many studies, since they 
directly and indirectly affect peripheral organs by activating signaling 
pathways which regulate the hormonal and nervous systems, 



















Figure 3. Formation process of SCFAs and their physiological importance. 
Obtained from [17].  
 
Regarding the uptake of SCFAs, they are transported through the 
intestinal mucosa thanks to an active transport chiefly mediated by two 
receptors: the sodium-coupled monocarboxylate transporter 1 (SMCT-1) 
and the monocarboxylate transporter 1 (MCT-1). In such a way, it is 
possible to directly inhibit histone deacetylases (HDAC) and 
consequently, by regulating gene expression and host physiology, to 
signal the effects of SCFA through G-protein-coupled receptors (GPCRs) 
[17]. 
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4.2 Mechanisms of Action  
 In the first place, it is necessary to emphasize that the vast majority 
of physiological activities that take place in the body are directed by 
intestinal metabolites. For this reason, SCFAs have been the subject of 
numerous studies in which it has been possible to demonstrate the key 
role that they exert by modulating the function of different systems, such 
as the intestinal, endocrine, nervous and blood systems, and, as a 
consequence, regulating metabolic disorders and immunity (Figure 3). 
Nevertheless, most of these effects have been shown in vitro and ex vivo 
studies and, therefore, convincing evidence in humans is still lacking 
[39].   
 
4.2.1 Appetite Regulation 
In different studies carried out in humans on the participation of 
NDCs, the modulating effect which it presents on energy consumption 
and appetite has been demonstrated [40,41]. In this sense, it has been 
observed that propionate produced in the intestine is capable of 
regulating food intake through peptide tyrosine-tyrosine (PYY) and 
glucagon-like peptide-1 (GLP-1) [42]. More specifically, the PYY 
participates both in the regulation of food intake and in satiety, through 
the activation of central Y receptor type 2 (Y2R) coupled to the G protein 
in neuropeptide Y (NPY) and agouti-related protein (AgRP) neurons, 
which are located in the arcuate nucleus of the hypothalamus [17]. 
Consequently, a signaling cascade is initiated, which inhibits appetite-
stimulating NPY neurons and finally, satiety is induced [43]. 
Other studies in mice have shown that the intake of oral probiotics, 
which are able to produce certain SCFAs such as sodium butyrate, 
increases transiently the secretion of GLP-1 and GIP (Gastric inhibitory 
polypeptide) [17,44]. In the case of GLP-1, there are studies in which is 
demonstrated that this hormone can increase insulin, inhibiting the 
secretion of glucagon located in the pancreas as well as gastric emptying 
and influencing both satiety and food intake [17,45,46]. Additionally, 
there is evidence that acetate can regulate appetite both through central 
hypothalamic mechanisms and by controlling satiety through acetate-
induced vagal activation or intestinal hormones [47]. 
Appetite regulation is coordinated by nutrients, like fiber, and 
microbial metabolites, as SCFAs do, through the central nervous system 
circuitry and circulating hormones from peripheral tissues [47]. 
Therefore, an impaired of this process it could have some significant 
implication in the development of obesity or certain metabolic diseases 
[17]. 
 
4.2.2 Glucose Homeostasis 
SCFAs act in concert to contribute to glucose and lipid 
homeostasis in the liver, through adenosine monophosphate-activated 
protein kinase (AMPK). Thereby, AMPK activation reduces the gene 
expression of glucose 6-phosphatase (G6Pase) and 
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phosphoenolpyruvate carboxy-kinase (PEPCK), both of enzymes 
playing an important role of gluconeogenesis [35].  
Other studies have shown that the activation of free fatty acid 
receptor 3 (FFAR3) by SCFA can stimulate the secretion of intestinal 
hormone PYY in endocrine cells [35]. As a consequence, it is an 
improvement of glucose absorption in adipose and muscle tissue, 
producing satiety and the food intake is reduced [48]. Regarding glucose 
transporter type 4 (GLUT4), a speed-limiting protein that allows glucose 
to enter muscle cells, SCFAs can increase its expression and translocate 
it to the cell membrane. As a result, the uptake of more glucose by 
myoblasts is promoted [35]. Furthermore, SCFAs can stimulate the 
production of GLP-1, by activating free fatty acid receptor 2 (FFAR2), 
which increase insulin secretion and decrease pancreatic glucagon, 
indirectly regulating blood glucose levels [35]. More specifically, 
different findings have observed a possible association between butyrate 
and insulin sensitivity, a fact which indicates that there is a relationship 
between the characteristics of the individual's intestinal microbiota and 
their glucose metabolism [1,49]. Hence, there is evidence that shows that 
SCFAs are capable of influencing insulin receptors, since a high-fiber diet 
modulates the intestinal microbiota and, as a consequence, there is an 
improvement in glucose metabolism in patients with type 2 diabetes 
mellitus [50,51]. Similarly, a deficit in the production of SCFAs has been 
related to an increased risk of type 2 diabetes mellitus, by interfering with 
the levels of glycosylated hemoglobin (HbA1c) [52].  
However, leptin plays an important role to balance blood glucose, 
as glucagon and insulin do [35]. It has been demonstrated that SCFAs 
can increase leptin secretion by activating FFAR2, both in vivo or in vitro. 
As follows, there is evidence indicating that this hormone promotes 
glucose uptake in brown adipose tissue and the soleus muscle. 
Moreover, leptin can directly promote the synthesis of glycogen in liver 
and muscle blood glucose uptake  [35]. 
 
4.2.3 Lipid Metabolism  
As members of the fatty acids group, SCFAs can be a substrate for 
a lipid synthesis in the organism. Hence, they exert their actions through 
their receptors, such as the GPR41 (FFAR3), GPR43 (FFAR2) and 
GPR109A, due to an activation of G-protein-coupled receptors and the 
inhibition of HDAC [17,53,54]. There is evidence which shows that 
acetate is a precursor in the synthesis of palmitate and stearate [55]. 
Thereby, the SCFAs are converted into acetyl-CoA, as a precursor in the 
synthesis of other triglycerides. Nevertheless, SCFAs are not only a 
substrate involved in lipid metabolism; they also can be a factor to 
regulate lipid metabolism [35]. Concerning to GPR41, there is evidence 
showing that the potency order of activation for this receptor is 
propionate firstly, butyrate secondly and acetate thirdly [56]. In more 
detail, through this receptor, SCFAs can control leptin release in adipose 
tissue and, to some extent, regulate body weight [17]. In this regard, 
propionate has been shown to be able to reduce fat deposition in the liver 
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and visceral organs [42]. Regarding GPR109A, also known as the niacin 
receptor 1 (NIACR1) or hydroxycarboxylic acid receptor 2 (HCA2), it has 
been found that it is mostly expressed in adipocytes activated by butyric 
acid, a fact that occurs in the immune cells as well [17]. The result of its 
activation is the suppression of lipolysis in adipocytes and, consequently, 
plasma levels of free fatty acids are reduced [57]. Moreover, butyrate can 
increase both the oxidation of fatty acids in brown adipose tissue and 
promote the browning of white tissue [58]. Besides, it can increase the 
number of multicellular adipose cells, reduce the size of adipose cells and 
improve the insulin resistance and the obesity caused by diet [35]. 
However, it must be taken into account that acetate is capable of 
increasing the synthesis of fatty acids through the acetylation of histones 
[59]. Furthermore, SCFAs have also been shown to participate in the 
metabolic functions of the liver through the FFAR3 signaling pathway 
[17,60]. 
 
4.2.4 Gut Integrity 
The barrier function of epithelial cells is the first line of defense in 
the intestine, separating the intestinal luminal contents from the host to 
ensure intestinal integrity [39]. The evidence concludes that SCFAs are 
the most important components to maintain the integrity of the intestinal 
barrier and they turn out to be the substrate to nourish the colonocytes, 
being butyrate the main source of energy used by colonic cells [61]. 
Nonetheless, the effect of SCFAs may be concentration-dependent 
[39,62,63]. 
SCFAs act mainly through the modification of the expression of 
tight junction proteins to regulate paracellular permeability, as well as 
the transport of solutes through channels between intestinal cells 
[64,65,66]. More specifically, butyrate appears to be the most important 
regulator of tight junctions, through the positive regulation of genes 
responsible for encoding tight junction proteins [39,67]. In this respect, a 
study has shown that butyrate improves the expression of tight junction 
proteins, such as claudin-1 (CLDN1) and zonula occludens-1 (ZO-1) and 
moreover, it is capable of suppressing the interleukin 10 (IL-10) receptor-
dependent expression of claudin-2 (CLDN2) to promote epithelial 
barrier function [39,68]. In addition, it can contribute to increase the 
expression of mucin 2 (MUC2), which is expressed on the surface of the 
intestinal mucosa and strengthens the mucosa layer to prevent the entry 
of luminal pathogens, and it also induces antimicrobial peptides (AMPs) 
production [69,70,71].  
SCFAs have been shown to help relieve gastrointestinal disorders, 
such as inflammatory bowel disease (Crohn's disease and ulcerative 
colitis) [53,72]. Particularly, these intestinal disorders are more 
frequently localized in the western part of the world, as a consequence 
of drastic changes in eating habits and lifestyle patterns [17]. In this 
regard, it has been demonstrated that the reduction in the flow of SCFAs 
predisposes to the appearance of intestinal disorders at the molecular 
level.  
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In another study, it was observed that those mice which were fed 
with a high-sugar diet and a high-fat diet finally presented an alteration 
in intestinal integrity [73]. Thereby, the expression of GPR43 was found 
to be decreased in people with Crohn's disease [74] and, thus, the 
addition of SCFAs and prebiotic fibers in food was recommended for 
treatment, because of SCFAs participate in the regulation of the tight 
junctions in the intestinal epithelium [73]. Using the C57BL/6 mouse 
model, it was observed that dietary fiber shifts the gut microbiome 
toward an increased butyrate production [75]. As a result, a positive 
regulation of the microbiota and of gene expression dependent on AMPK 
was found, a fact that led to an improvement in intestinal integrity [75]. 
 
4.2.5 Anti-oxidative Effects 
SCFAs can influence the inflammatory process as well as 
carcinogenesis. In both, there is a situation of oxidative stress due to an 
imbalance between the oxidizing substances found in the body and the 
endogenous antioxidant system of the host [39]. In such situations, there 
is scientific evidence which shows that SCFAs, mainly butyrate, are 
capable of modulating oxidative stress [39,76]. Hence, it has been 
observed that incubation of rat or human colonocytes with butyrate 
significantly reduces the levels of DNA damage produced by hydrogen 
peroxide (H2O2) [39]. In this line, it is suggested that the antioxidant 
function of SCFAs takes place thanks to the regulation of oxidoreductase 
[39,77]. Furthermore, butyrate has been shown to significantly increase 
the activities of different antioxidant enzymes, such as glutathione 
reductase (GR), glutathione peroxidase (GPx) and catalase (CAT), to 
induce apoptosis in MCF-7 human breast cancer cells [39]. More 
evidence in in vitro studies indicates that antioxidant enzymes, such as 
superoxide dismutase-2 (SOD2) and CAT, increased after butyrate 
treatment [70]. Moreover, butyrate can suppress oxidative stress induced 
by a high-fat diet in the rat liver, through the nuclear factor erythroid 2-
related factor 2 (NRF2) pathway and mitochondrial function [78]. In 
healthy humans, locally administered butyrate at physiological 
concentrations has been shown to increase antioxidant glutathione and 
probably decrease reactive oxygen species (ROS) production, due to a 
decreased in uric acid production [39]. In short, in a broad sense, SCFAs 
prevent the production of ROS and reactive nitrogen species (RNS) [39]. 
 
4.2.6 Anti-inflammatory and Immuno-modulatory Effects 
The anti-inflammatory and immuno-modulatory effects of SCFAs 
involve both the activation of GPR41 / FFAR3, GPR43 / FFAR2 and 
GPR109A receptors, and moreover, inhibiting HDACs activity [79]. 
Particularly, in reference to the immuno-modulatory effects, different 
findings have demonstrated the capacity of SCFAs to configure and 
modulate the immune system, in its local and peripheral form, regulated 
through inflammatory pathways [17]. In this regard, the evidence that 
exists on the subject shows that SCFAs can have a strong impact on the 
modulation of both the innate and adaptive immune systems [79]. In this 
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sense, a study carried out in mice showed that those which were deficient 
in GPR43 developed arthritis, colitis and asthma. Thus, a direct action of 
SCFA on the T regulatory (Treg) cells of the colon was demonstrated, 
through the increase of the gene expression of GPR43 [79,80]. 
On the one hand, butyrate can modulate the activity of GPR109A, 
regulating the pro-inflammatory activities of phagocytic cells in the 
colon. Moreover, it is known that it contributes to the differentiation of 
Treg cells, as well as to the production of anti-inflammatory cytokines 
such as IL-10 and decreases the colonic epithelial secretion of IL-6, IL-18, 
and tumor necrosis factor (TNF-α), which are pro-inflammatory 
cytokines [79]. 
On the other hand, propionate and acetate are capable to improve 
Treg cells function too. In more detail, it is probably that commensal 
bacterial species in the gut promote inducible Tregs cells through SCFAs 
release [79]. Furthermore, it has been shown that propionate increases 
the phagocytic capacity of dendritic cells in the bone marrow and is able 
to limit their capacity ability to trigger a T helper type 2 (Th2) response 
in the airways, through its binding to GPR41 [79,81]. 
In general, it has been shown that SCFAs increase the 
immunoglobulin A (IgA) response at the intestinal level and 
immunoglobulin G (IgG) at the systemic level and, probably by 
promoting the differentiation of plasma B cells is promoted. Thusly, 
studies carried out with mice exposed to a low-fiber diet and, 
consequently, a low synthesis of SCFA, have shown to induce an 
imbalance of antibodies and, as a result, they have been more susceptible 
to suffering from infections [82]. 
5. Discussion 
In this manuscript, the numerous beneficial effects of dietary fiber 
consumption have been reported, especially due to the SCFAs 
generation. However, there may be a wide range of situations in which 
caution is warranted in making generalizable recommendations on fiber 
intake to the general population [18]. More specifically, in cases of people 
with irritable bowel syndrome, the intake of fiber can cause undesirable 
side effects, such as bloating, flatulence, stomach pain, constipation and 
diarrhea [18]. In this line, different investigations using animal models 
suggest that the metabolites which are generated after fiber ingestion can 
have a strong negative impact on health in people suffering from colitis 
or colorectal cancer [83,84]. However, it should be noted, that tolerance 
to dietary fiber depends on the individual and, in most cases, improves 
with time as higher doses of fiber are ingested thanks to an adaptation 
by the gastrointestinal tract and the microbiota [85].  
Hence, the main problem that must be solved in the development of 
this approach is that, many studies, in vitro (cells) and in vivo (animal 
models), have been conducted, but research in humans is still scarce  [39]. 
In addition, most of the current studies focus on a single SCFA, and do 
not consider the synergistic effects of all SCFAs and exposure times used. 
Nevertheless, this limitation could be overcome by the combined 
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application of different administrations of acetate, propionate and 
butyrate at different times [39]. Thus, the lack of deep and detailed 
knowledge about the functioning of the bacterial consortia which are 
part of the human intestinal microbiota is another challenge to overcome, 
as well as the high amount of dietary fiber that would be necessary to 
produce significant results in the host [39]. Moreover, the wide 
variability in the response to dietary modification due to the resistance 
to change of certain microbial strains is another limitation, along with the 
need to develop new forms of dietary fiber supplements which are 
tolerable and palatable when were ingested in effective amounts [86]. 
However, precision, personalized, preventive and predictive 
medicine based on epigenetics, microbiomics and metabolomics may not 
be far off to be the medicine in the more or less near future. Science and 
technology will have advanced enough so that people can go to a health 
center and submit their saliva, skin, blood, breath and stool samples. 
Thusly, said samples will be analyzed in automated machines by 
standardized protocols that will check what microorganisms the 
individual has in situ and which metabolites they produce. In addition, 
the complete genome will already be sequenced, and it will be known 
how it is associated with the human microbiome [87]. Based on these 
results, hand in hand with artificial intelligence and big data, through 
complex algorithms based on systems medicine, the computer will allow 
the preparation of a report with the dietary recommendations for the 
individual, simultaneously informing of the bacterial consortia the host 
need. Besides, itself will carry out an exhaustive analysis of the health 
risks linked to a series of detailed advice so that the individual can know 
and apply [87]. As follows, specific types of fiber could be used 
individually combined with the host's own microbiota profile to reduce 
the severity of side effects, while providing a beneficial physiological 
effect to the body [18]. In this manner, if there were the ability to identify 
some key bacteria and their metabolites related to the appearance or 
generation of a disease or protection against it, the microbiota of the 
affected individual could be precisely treated [39]. 
 
6. Conclusions 
The intestinal microbiota has been the focus of researchers in recent 
years. Dietary fiber is considered a key compound to preserve gut health 
thanks to the SCFAs, which the microbiota produce during the fiber 
fermentation process and they play important roles in homeostasis and 
regulation of host physiology. For a better understanding of the 
interactions between diet and microbiota, it would be necessary to 
develop a personalized nutrition approach. It would more efficiently 
reduce the incidence of many of the diseases currently present and serves 
as a diagnostic tool. Therefore, given the different current gaps which 
exist on this topic, more scientific evidence is required that can be 
translated into clinical practice, since the field of microbiota research 
presents enormous potential. 
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